Catalyst Wire Dossier Catalyst Wire Dossier

SPA100

aliskiren/amlodipine · Novartis
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for SPA100, covering 2012-06-13 to 2012-06-13. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension [Phase 3]

See pricing